Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group.

@article{Mller2001OpipramolFT,
  title={Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group.},
  author={H. J. M{\"o}ller and H. P. Volz and Ingrid W. Reimann and Katrin Stoll},
  journal={Journal of clinical psychopharmacology},
  year={2001},
  volume={21 1},
  pages={
          59-65
        }
}
Opipramol, a drug widely prescribed in Germany, is a tricyclic compound with no reuptake-inhibiting properties. However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). In early controlled trials, anxiolytic effects were revealed. However, those studies were performed before the concept of generalized anxiety disorder (GAD) was established. Because of the interesting receptor-binding profile and promising results of the early… CONTINUE READING
Highly Cited
This paper has 54 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

[Update Opipramol].

Fortschritte der Neurologie-Psychiatrie • 2017
View 6 Excerpts
Method Support
Highly Influenced

54 Citations

0510'02'05'09'13'17
Citations per Year
Semantic Scholar estimates that this publication has 54 citations based on the available data.

See our FAQ for additional information.